RIS ID
111813
Abstract
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?
111813
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?
Publication Details
Taylor, R. S., Drummond, M. F., Salkeld, G. & Sullivan, S. D. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle. BMJ: British Medical Journal, 329 (7472), 972-975.